Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 8

1.

Incidental findings in pancreas screening programs for high-risk individuals: Results from three European expert centers.

Ibrahim IS, Brückner C, Carrato A, Earl J, Inderson A, de Vos Tot Nederveen Cappel WH, Mintziras I, Matthäi E, Figiel J, Wasser M, Moreau H, Bonsing B, Slater EP, Bartsch DK, Vasen HF.

United European Gastroenterol J. 2019 Jun;7(5):682-688. doi: 10.1177/2050640619841989. Epub 2019 Mar 31.

2.

German National Case Collection for familial pancreatic Cancer (FaPaCa) - acceptance and psychological aspects of a pancreatic cancer screening program.

Franke FS, Matthäi E, Slater EP, Schicker C, Kruse J, Bartsch DK.

Hered Cancer Clin Pract. 2018 Nov 29;16:17. doi: 10.1186/s13053-018-0100-6. eCollection 2018.

3.

The Combination of MiRNA-196b, LCN2, and TIMP1 is a Potential Set of Circulating Biomarkers for Screening Individuals at Risk for Familial Pancreatic Cancer.

Bartsch DK, Gercke N, Strauch K, Wieboldt R, Matthäi E, Wagner V, Rospleszcz S, Schäfer A, Franke FS, Mintziras I, Bauer C, Grote T, Figiel J, Di Fazio P, Burchert A, Reinartz S, Pogge von Strandmann E, Klöppel G, Slater EP.

J Clin Med. 2018 Sep 20;7(10). pii: E295. doi: 10.3390/jcm7100295.

4.

Benefit of Surveillance for Pancreatic Cancer in High-Risk Individuals: Outcome of Long-Term Prospective Follow-Up Studies From Three European Expert Centers.

Vasen H, Ibrahim I, Ponce CG, Slater EP, Matthäi E, Carrato A, Earl J, Robbers K, van Mil AM, Potjer T, Bonsing BA, de Vos Tot Nederveen Cappel WH, Bergman W, Wasser M, Morreau H, Klöppel G, Schicker C, Steinkamp M, Figiel J, Esposito I, Mocci E, Vazquez-Sequeiros E, Sanjuanbenito A, Muñoz-Beltran M, Montans J, Langer P, Fendrich V, Bartsch DK.

J Clin Oncol. 2016 Jun 10;34(17):2010-9. doi: 10.1200/JCO.2015.64.0730. Epub 2016 Apr 25.

PMID:
27114589
5.

MicroRNA-196a and -196b as Potential Biomarkers for the Early Detection of Familial Pancreatic Cancer.

Slater EP, Strauch K, Rospleszcz S, Ramaswamy A, Esposito I, Klöppel G, Matthäi E, Heeger K, Fendrich V, Langer P, Bartsch DK.

Transl Oncol. 2014 Aug;7(4):464-71. doi: 10.1016/j.tranon.2014.05.007. Epub 2014 Jun 21.

6.

LCN2 and TIMP1 as Potential Serum Markers for the Early Detection of Familial Pancreatic Cancer.

Slater EP, Fendrich V, Strauch K, Rospleszcz S, Ramaswamy A, Mätthai E, Chaloupka B, Gress TM, Langer P, Bartsch DK.

Transl Oncol. 2013 Apr;6(2):99-103. Epub 2013 Apr 1.

7.

German national case collection for familial pancreatic cancer (FaPaCa): ten years experience.

Schneider R, Slater EP, Sina M, Habbe N, Fendrich V, Matthäi E, Langer P, Bartsch DK.

Fam Cancer. 2011 Jun;10(2):323-30. doi: 10.1007/s10689-010-9414-x.

PMID:
21207249
8.

Prevalence of BRCA2 and CDKN2a mutations in German familial pancreatic cancer families.

Slater EP, Langer P, Fendrich V, Habbe N, Chaloupka B, Matthäi E, Sina M, Hahn SA, Bartsch DK.

Fam Cancer. 2010 Sep;9(3):335-43. doi: 10.1007/s10689-010-9329-6.

PMID:
20195775

Supplemental Content

Loading ...
Support Center